Esperion counsel sells 1,689 shares for taxes

Esperion Therapeutics General Counsel Benjamin Looker reported a small sale of company stock.

Rhea-AI Filing Summary

Esperion Therapeutics General Counsel Benjamin Looker reported a small sale of company stock. On 01/20/2026, he sold 1,689 shares of Esperion Therapeutics common stock at a price of $2.882 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the transaction was linked to covering taxes rather than a discretionary open-market sale. Following this transaction, he beneficially owned 384,216 shares directly.

Insider Trade Summary

Net Seller: 1,689 shares

Net Sell 1 txn

Insider Looker Benjamin

Role General Counsel

Sold 1,689 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,689	$2.882	$5K

Holdings After Transaction: Common Stock — 384,216 shares (Direct)

Footnotes (1)

1. F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ESPR's General Counsel report?

Esperion Therapeutics, Inc. General Counsel Benjamin Looker reported selling 1,689 shares of common stock on 01/20/2026 at a price of $2.882 per share.

Why did Benjamin Looker sell Esperion Therapeutics (ESPR) shares?

The filing states that the 1,689 shares were sold "to satisfy tax obligation on vested shares of restricted stock units," indicating the sale was for tax withholding purposes.

How many ESPR shares does the General Counsel own after this transaction?

After the reported sale, Benjamin Looker beneficially owned 384,216 shares of Esperion Therapeutics common stock directly.

Is the Esperion Therapeutics insider transaction direct or through another entity?

The transaction is reported as direct ownership (D), with no indication that the shares are held through a separate entity or trust.

What role does the reporting person hold at Esperion Therapeutics (ESPR)?

The reporting person, Benjamin Looker, is an officer of Esperion Therapeutics, Inc., serving as General Counsel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 05:17 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Looker Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		1,689(1)	D	$2.882	384,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.